Literature DB >> 21287410

Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II).

Siobhan Gallanagh1, Davide Castagno, Ben Wilson, Erland Erdmann, Faiez Zannad, Willem J Remme, José L Lopez-Sendon, Philippe Lechat, Ferenc Follath, Christer Höglund, Viacheslav Mareev, Zygmunt Sadowski, Ricardo J Seabra-Gomes, Henry J Dargie, John J V McMurray.   

Abstract

AIMS: We evaluated a generic quality of life (QoL) Functional Status Questionnaire (FSQ), in patients with chronic heart failure (CHF). The FSQ assesses the 3 main dimensions of QoL: physical functioning, mental health and social role. It also includes 6 single item questions about: work status, frequency of social interactions, satisfaction with sexual relationships, days in bed, days with restricted activity and overall satisfaction with health status. The FSQ was compared to the Minnesota Living with Heart Failure questionnaire (MLwHF). METHODS AND
RESULTS: The FSQ was evaluated in a substudy (n = 340) of the second Cardiac Insufficiency Bisoprolol Survival study (CIBIS-II), a placebo-controlled mortality trial. 265 patients (75%) patients completed both questionnaires at 6 months of follow-up. Both questionnaires indicated substantially impaired QoL. The FSQ demonstrated high internal consistency (Cronbach's α > 0.7 for all items except "social activity" = 0.66) and construct and concurrent validity. After 6 months, the only item on either questionnaire to show a difference between the placebo- and bisoprolol-treatment groups was the single item FSQ question about "days in bed" (p = 0.018 in favour of bisoprolol).
CONCLUSIONS: The FSQ performed well in this study, provided additional information to the MLwHF questionnaire and allowed interesting comparisons with other chronic medical conditions. The FSQ may be a useful general QoL instrument for studies in CHF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21287410     DOI: 10.1007/s10557-011-6284-x

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  5 in total

1.  Volume to Value: Defining the Value of Cardiovascular Imaging.

Authors:  Sangeeta B Shah; Tripti Gupta; Kyle D Severinsen; Elizabeth McIlwain; Christopher J White
Journal:  Ochsner J       Date:  2016

2.  Assessing the impact of heart failure therapeutics on quality of life and functional capacity.

Authors:  Eldrin F Lewis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-08

Review 3.  Assessing quality-of-life outcomes in cardiovascular clinical research.

Authors:  Daniel B Mark
Journal:  Nat Rev Cardiol       Date:  2016-02-18       Impact factor: 32.419

4.  Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.

Authors:  Alvin Chandra; Eldrin F Lewis; Brian L Claggett; Akshay S Desai; Milton Packer; Michael R Zile; Karl Swedberg; Jean L Rouleau; Victor C Shi; Martin P Lefkowitz; Tzvetana Katova; John J V McMurray; Scott D Solomon
Journal:  JAMA Cardiol       Date:  2018-06-01       Impact factor: 14.676

5.  Pharmacological interventions for heart failure in people with chronic kidney disease.

Authors:  Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani
Journal:  Cochrane Database Syst Rev       Date:  2020-02-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.